Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the… Read more
Palisade Bio Inc (PALI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.106x
Based on the latest financial reports, Palisade Bio Inc (PALI) has a cash flow conversion efficiency ratio of -1.106x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.55 Million) by net assets ($3.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Palisade Bio Inc - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Palisade Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Palisade Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palisade Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fidelity D&D Bancorp Inc
NASDAQ:FDBC
|
0.037x |
|
SIGA Technologies Inc
NASDAQ:SIGA
|
-0.048x |
|
Changzhou Shenli Electrical Machine Incorporated Co
SHG:603819
|
0.017x |
|
Shenzhen Friendcom Technology Development Co Ltd
SHE:300514
|
0.074x |
|
Alkane Resources Ltd
AU:ALK
|
0.156x |
|
Civeo Corp
NYSE:CVEO
|
0.076x |
|
Hong Tai Electric Industrial Co Ltd
TW:1612
|
0.033x |
|
Proact IT Group AB
ST:PACT
|
0.368x |
Annual Cash Flow Conversion Efficiency for Palisade Bio Inc (2005–2024)
The table below shows the annual cash flow conversion efficiency of Palisade Bio Inc from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.49 Million | $-12.19 Million | -1.627x | -65.38% |
| 2023-12-31 | $11.31 Million | $-11.13 Million | -0.984x | +8.08% |
| 2022-12-31 | $12.48 Million | $-13.36 Million | -1.071x | +46.63% |
| 2021-12-31 | $7.37 Million | $-14.77 Million | -2.006x | -398.65% |
| 2020-12-31 | $-7.10 Million | $-4.77 Million | 0.672x | +147.45% |
| 2019-12-31 | $5.13 Million | $-7.26 Million | -1.415x | -11.32% |
| 2018-12-31 | $6.05 Million | $-7.69 Million | -1.272x | +19.29% |
| 2017-12-31 | $8.52 Million | $-13.42 Million | -1.576x | -14.32% |
| 2016-12-31 | $11.33 Million | $-15.62 Million | -1.378x | +63.84% |
| 2015-12-31 | $4.97 Million | $-18.93 Million | -3.811x | -476.88% |
| 2014-12-31 | $17.72 Million | $-11.71 Million | -0.661x | +47.49% |
| 2013-12-31 | $8.42 Million | $-10.59 Million | -1.258x | -3.48% |
| 2012-12-31 | $6.97 Million | $-8.48 Million | -1.216x | +75.08% |
| 2011-12-31 | $1.66 Million | $-8.10 Million | -4.878x | -283.86% |
| 2010-12-31 | $7.85 Million | $-9.98 Million | -1.271x | -223.88% |
| 2009-12-31 | $-5.02 Million | $-5.14 Million | 1.026x | +162.85% |
| 2008-12-31 | $4.20 Million | $-6.86 Million | -1.632x | -177.74% |
| 2007-12-31 | $6.81 Million | $-4.00 Million | -0.588x | +72.65% |
| 2006-12-31 | $1.55 Million | $-3.33 Million | -2.148x | -235.69% |
| 2005-12-31 | $-460.17K | $-728.59K | 1.583x | -- |